NurseJet
Back to Discover
Research ArticleResearchMedication Safety

Azacitidine-venetoclax prolonged event-free survival in a selected induction-eligible AML population

The New England journal of medicine (PubMed)Sep 3, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A phase 2 randomized trial favored azacitidine-venetoclax over induction chemotherapy for event-free survival in selected adults with untreated AML.

What NurseJet pulled from the source

Among 172 participants, median event-free survival was 14.5 versus 6.2 months (hazard ratio for event or death 0.57; 95% CI 0.39-0.84). Median follow-up was 21.9 months.

Why this matters for nurses

The result informs treatment discussions, while serious infection and bleeding remain relevant nursing concerns.

Bedside takeaway

Avoid generalizing this phase 2 result to every patient with AML.

How This Applies in Practice

Use this when: Explaining treatment evidence to a patient with AML.

On your shift

  • Clarify that eligibility and molecular findings affect how this trial applies.
Keep in mind: Treatment selection belongs with the oncology team; follow facility policy and provider orders.

Key takeaways

  • Grade 3 or higher infection occurred in 28% versus 41%, respectively.
  • Grade 3 or higher hemorrhage occurred in 2% versus 12%, respectively.

Practice implications

  • Reinforce the individualized oncology plan and communicate infection or bleeding concerns promptly.

Limitations & cautions

  • Abstract-only summary of an industry-funded phase 2 trial. Core-binding-factor fusions, FLT3 mutations, and NPM1 mutations in patients under 60 were excluded. Event-free survival is not overall survival.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The New England journal of medicine (PubMed)

The New England journal of medicine (PubMed). Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42685316/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Neurosurgical review (PubMed)

A systematic review and meta-analysis of 14 studies comprising 7,981 patients found extending single-agent antibiotic prophylaxis beyond one day did not reduce postoperative meningitis after endoscopic endonasal skull base surgery, whereas intraoperative CSF leak significantly increased infection risk.

Med-SurgAI summaryReview source

Anesthesia and analgesia (PubMed)

A meta-analysis of 25 randomized controlled trials with 3,344 surgical patients found perioperative ketamine and esketamine were associated with reduced postoperative delirium between days 2 and 7, but significantly increased postoperative dizziness.

GeriatricsMed-SurgAI summaryReview source

Western journal of nursing research (PubMed)

A systematic review and meta-analysis of 38 studies including 19,033 patients identified clinical severity scales—specifically Modified Fisher grade and Fisher grade—and hemodynamic status as the strongest predictors of cerebral vasospasm following subarachnoid hemorrhage.

EmergencyICUAI summaryReview source